Experimental Cardiovascular Research Unit, Department of Clinical Sciences Malmö, Lund University, Clinical Research Center 91:12, Jan Waldenströms gata 35, SE-214 28 Malmö, Sweden.
Experimental Cardiovascular Research Unit, Department of Clinical Sciences Malmö, Lund University, Clinical Research Center 91:12, Jan Waldenströms gata 35, SE-214 28 Malmö, Sweden; Department of Cardiology, Skåne University Hospital Malmö, Inga Marie Nilssons gata 46, Floor 2, SE-214 28 Malmö, Sweden.
Cytokine. 2019 Oct;122:154208. doi: 10.1016/j.cyto.2017.11.002. Epub 2018 Feb 7.
IL-27 is an immunoregulatory cytokine belonging to the IL-6/IL-12 family that was found to be elevated in acute coronary syndrome (ACS) patients. We investigated whether IL-27 is related to post-ischemic cardiac remodeling and long-term prognosis in this patient group.
We included 524 ACS patients, defined as acute myocardial infarction (AMI) or unstable angina (UA). A subgroup of 107 patients donated blood samples 6 weeks after the index event, and underwent a follow-up echocardiographical examination at 1 year. We measured plasma levels of IL-27, high sensitivity troponin T (hsTNT), C-reactive protein (hsCRP) and cystatin C at baseline and in the 6-week samples. The median follow-up period of the cohort was 2.2 years.
The incidence of the combined end-point of AMI and cardiovascular death was higher in patients with plasma IL-27 within the top two tertiles both at baseline and after 6 weeks. After correction for cardiovascular risk factors, medication, hsTNT, hsCRP, and eGFR, patients with baseline IL-27 levels within the highest tertile had a significantly elevated risk for the combined end-point compared with the lowest tertile (hazard ratio 2.70, 95% CI 1.06-6.90, p = .038). Additionally, higher baseline IL-27 levels were associated with deleterious left ventricular remodeling and deterioration of systolic and diastolic function during the first year of follow-up.
Elevated IL-27 at the time of an ACS is independently related to impaired cardiac function and worse long-term prognosis. Our data warrants further mechanistic studies to elucidate the involvement of IL-27 in cardiac repair and remodeling after ACS.
IL-27 是一种免疫调节细胞因子,属于 IL-6/IL-12 家族,在急性冠状动脉综合征(ACS)患者中发现其水平升高。我们研究了 IL-27 是否与该患者群体的缺血后心脏重构和长期预后有关。
我们纳入了 524 例 ACS 患者,定义为急性心肌梗死(AMI)或不稳定型心绞痛(UA)。其中 107 例患者亚组在指数事件后 6 周捐献血液样本,并在 1 年后进行了随访超声心动图检查。我们在基线和 6 周样本中测量了 IL-27、高敏肌钙蛋白 T(hsTNT)、C 反应蛋白(hsCRP)和胱抑素 C 的血浆水平。该队列的中位随访时间为 2.2 年。
在基线和 6 周时,IL-27 血浆水平在前两个三分位的患者中,AMI 和心血管死亡的联合终点发生率更高。在校正心血管危险因素、药物、hsTNT、hsCRP 和 eGFR 后,基线 IL-27 水平处于最高三分位的患者与最低三分位的患者相比,联合终点的风险显著升高(风险比 2.70,95%CI 1.06-6.90,p=0.038)。此外,较高的基线 IL-27 水平与左心室重构不良以及在随访的第一年心功能收缩和舒张功能恶化相关。
ACS 时升高的 IL-27 与受损的心脏功能和较差的长期预后独立相关。我们的数据需要进一步的机制研究来阐明 IL-27 在 ACS 后心脏修复和重构中的作用。